Free Trial
→ Man who predicted $100K Bitcoin sees a huge run coming for another coin … (From Weiss Ratings) (Ad) Buy AZN Stock  Free AZN Stock Alerts

AstraZeneca (AZN) Financials

AstraZeneca logo
$70.96 +0.55 (+0.78%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$70.67 -0.29 (-0.41%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for AstraZeneca

Annual Income Statements for AstraZeneca

This table shows AstraZeneca's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 18,113 17,086 9,261 -167 11,632 2,058 3,985 12,887 12,887 12,366
Consolidated Net Income / (Loss)		 18,102 17,074 9,254 -173 11,736 1,227 4,196 13,153 13,074 12,365
Net Income / (Loss) Continuing Operations		 18,102 17,074 9,254 -173 11,736 141 4,196 13,153 13,074 12,365
Total Pre-Tax Income 		18,102 17,074 9,254 -265 11,736 1,548 4,196 12,512 13,220 12,640
Total Operating Income		 19,821 18,674 10,611 1,961 12,489 2,924 6,697 12,285 14,797 12,531
Total Gross Profit		 43,866 37,543 31,960 24,980 21,318 19,463 17,154 18,147 18,876 20,062
Total Revenue		 63,940 56,432 50,184 37,919 33,932 24,384 25,537 25,579 26,568 27,579
Operating Revenue		 63,940 56,432 50,184 37,919 33,932 - 25,537 25,579 26,568 27,579
Total Cost of Revenue		 10,762 8,807 12,927 12,889 5,698 4,921 5,321 -719 -2,798 -1,219
Operating Cost of Revenue		 10,762 8,807 12,927 12,889 5,698 4,921 5,321 -719 -2,798 -1,219
Total Operating Expenses		 33,357 28,951 26,646 23,019 15,745 17,741 13,519 14,013 14,569 16,267
Selling, General & Admin Expense		 19,897 19,622 17,301 14,608 11,462 11,682 10,077 10,233 9,413 11,112
Research & Development Expense		 13,583 10,935 9,762 9,736 5,991 6,059 5,932 5,757 5,890 5,997
Other Operating Expenses / (Income)		 -123 -1,606 -417 -1,325 -1,708 - -2,490 -1,977 -734 -842
Total Other Income / (Expense), net		 -1,719 -1,600 -1,357 -2,134 -753 -1,260 -2,501 227 -1,577 109
Other Income / (Expense), net		 -1,719 -1,600 -1,357 -2,134 -753 - -2,509 226 -1,578 108
Net Income / (Loss) Attributable to Noncontrolling Interest		 -11 -12 -7.00 -6.00 104 -108 211 266 187 -1.00
Basic Earnings per Share		 $4.54 $3.84 $2.12 - $2.44 $1.03 $1.70 $2.37 $2.77 $2.23
Weighted Average Basic Shares Outstanding		 1.55B 1.55B 1.55B 1.42B 1.31B 1.30B 1.27B 1.27B 1.27B 1.26B
Diluted Earnings per Share		 $4.50 $3.81 $2.11 - $2.44 $1.03 $1.70 $2.37 $2.76 $2.23
Weighted Average Diluted Shares Outstanding		 1.56B 1.56B 1.56B 2.85B 1.31B 1.30B 1.27B 1.27B 1.27B 1.27B
Weighted Average Basic & Diluted Shares Outstanding		 1.55B 1.55B 1.55B 1.42B 1.31B 1.30B 1.27B 1.27B - -

Quarterly Income Statements for AstraZeneca

No quarterly income statements for AstraZeneca are available.

Annual Cash Flow Statements for AstraZeneca

This table details how cash moves in and out of AstraZeneca's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 20,354 10,520 13,786 20,121 5,208 547 1,537 -1,686 -1,148 4,280
Net Cash From Operating Activities		 18,501 15,462 15,057 11,175 6,817 2,969 7,939 3,578 4,145 5,164
Net Cash From Continuing Operating Activities		 18,501 15,462 15,057 11,175 6,817 -128 7,939 1,536 4,588 5,164
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 0.00 0.00 1,548 0.00 2,227 3,552 0.00
Depreciation Expense		 6,688 5,387 5,480 6,530 3,149 - - - - 2,852
Non-Cash Adjustments To Reconcile Net Income		 11,813 10,075 9,577 4,645 3,668 -1,772 8,476 926 181 2,312
Net Cash From Investing Activities		 13 0.00 0.00 776 0.00 657 -626 -2,328 -3,969 0.00
Net Cash From Continuing Investing Activities		 13 0.00 0.00 776 0.00 -98 -626 -1,894 -3,663 0.00
Purchase of Investments		 13 - 0.00 776 - -1,494 405 -96 -1,098 -
Net Cash From Financing Activities		 1,840 -4,942 -1,271 8,170 -1,609 1,765 -4,982 -2,936 -1,324 -884
Net Cash From Continuing Financing Activities		 1,840 -4,942 -1,271 8,170 -1,609 -737 -4,982 -2,916 -1,326 -884
Repayment of Debt		 -4,652 -4,942 -1,271 -4,759 -1,609 -1,686 -1,400 -1,764 0.00 -884
Issuance of Debt		 6,492 - - 12,929 - 500 -98 1,988 2,491 -
Cash Interest Received		 343 287 60 34 47 - 193 - - 123

Quarterly Cash Flow Statements for AstraZeneca

No quarterly cash flow statements for AstraZeneca are available.

Annual Balance Sheets for AstraZeneca

This table presents AstraZeneca's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 104,035 101,119 96,483 105,363 66,729 61,377 60,651 63,354 62,526 60,056
Total Current Assets		 25,827 25,054 22,593 26,244 19,544 15,563 15,591 13,150 13,262 16,007
Cash & Equivalents		 5,488 5,840 6,166 6,329 7,832 5,369 4,831 3,324 5,018 6,240
Short-Term Investments		 220 238 326 152 302 885 1,107 1,258 911 615
Accounts Receivable		 12,972 12,126 10,521 9,644 7,022 5,761 5,574 5,009 4,573 6,622
Inventories, net		 5,288 5,424 4,699 9,351 4,024 3,263 3,872 3,035 2,334 2,143
Current Deferred & Refundable Income Taxes		 1,859 1,426 731 663 364 285 207 524 426 387
Plant, Property, & Equipment, net		 10,252 9,402 8,507 9,183 8,251 7,688 7,421 7,615 6,848 6,413
Plant, Property & Equipment, gross		 10,252 9,402 8,507 9,183 8,251 7,688 7,421 7,615 6,848 6,413
Total Noncurrent Assets		 67,956 66,663 65,383 27,549 17,987 38,126 37,639 42,589 42,416 37,636
Long-Term Investments		 1,900 1,677 1,142 1,237 1,147 1,459 922 1,036 826 543
Noncurrent Note & Lease Receivables		 930 803 835 895 720 740 515 847 901 907
Goodwill		 21,025 20,048 19,820 19,997 11,845 11,668 11,707 11,825 11,658 11,800
Intangible Assets		 37,177 38,089 39,307 - - 20,833 21,959 26,188 27,586 22,646
Noncurrent Deferred & Refundable Income Taxes		 5,347 4,718 3,263 4,330 3,438 2,718 2,379 2,189 1,102 1,294
Other Noncurrent Operating Assets		 1,577 1,328 1,016 1,090 837 708 157 504 343 446
Total Liabilities & Shareholders' Equity		 102,624 99,655 95,015 103,919 65,306 59,331 59,211 61,926 61,080 58,621
Total Liabilities		 63,164 61,953 59,425 66,076 51,091 46,781 46,607 46,712 45,857 41,547
Total Current Liabilities		 27,866 30,542 26,293 22,594 20,307 18,117 16,292 16,383 15,256 14,869
Short-Term Debt		 2,337 5,129 5,314 1,660 2,194 1,822 1,754 2,247 2,307 916
Accounts Payable		 22,465 22,374 19,040 18,938 15,785 13,987 12,841 11,641 10,486 11,663
Current Deferred & Payable Income Tax Liabilities		 1,406 1,584 896 916 1,127 1,361 1,164 - 1,380 1,483
Other Current Liabilities		 1,658 1,455 1,043 1,080 1,201 947 533 1,145 1,083 807
Total Noncurrent Liabilities		 35,298 31,411 33,132 43,482 30,784 28,664 30,315 30,329 30,601 26,678
Long-Term Debt		 26,506 22,365 22,965 28,134 17,507 15,730 17,359 15,560 14,501 14,137
Capital Lease Obligations		 1,113 857 725 754 489 487 0.00 0.00 - -
Noncurrent Deferred & Payable Income Tax Liabilities		 3,543 2,844 2,944 6,206 2,918 2,490 3,286 3,995 3,956 2,665
Noncurrent Employee Benefit Liabilities		 1,330 1,520 1,168 2,454 3,202 2,807 2,511 2,583 2,186 1,974
Other Noncurrent Operating Liabilities		 2,806 3,825 5,330 5,934 6,668 7,150 7,159 8,191 9,958 7,902
Total Equity & Noncontrolling Interests		 39,460 37,702 35,590 37,843 14,215 14,596 12,604 15,214 15,223 17,074
Total Preferred & Common Equity		 81,657 78,309 74,095 78,555 31,260 11,081 26,512 31,602 31,523 36,999
Preferred Stock		 35,226 35,188 35,155 35,126 7,971 - 4,427 4,393 4,351 4,304
Total Common Equity		 4,149 2,491 414 2,698 6,228 13,127 6,601 9,139 9,057 12,751
Common Stock		 388 388 387 387 328 328 317 317 316 316
Retained Earnings		 3,160 1,502 -574 1,710 5,299 2,812 5,683 8,221 8,140 11,834
Other Equity Adjustments		 601 601 601 601 601 7,941 601 601 601 601
Noncontrolling Interest		 85 23 21 19 16 1,469 1,576 1,682 1,815 19

Quarterly Balance Sheets for AstraZeneca

This table presents AstraZeneca's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q4 2023 Q4 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 104,035 101,119 96,483
Total Current Assets		 25,827 25,054 22,593
Cash & Equivalents		 5,488 5,840 6,166
Short-Term Investments		 220 238 326
Accounts Receivable		 12,972 12,126 10,521
Inventories, net		 5,288 5,424 4,699
Current Deferred & Refundable Income Taxes		 1,859 1,426 731
Plant, Property, & Equipment, net		 10,252 9,402 8,507
Plant, Property & Equipment, gross		 10,252 9,402 8,507
Total Noncurrent Assets		 67,956 66,663 65,383
Long-Term Investments		 1,900 1,677 1,142
Noncurrent Note & Lease Receivables		 930 803 835
Goodwill		 21,025 20,048 19,820
Intangible Assets		 37,177 38,089 39,307
Noncurrent Deferred & Refundable Income Taxes		 5,347 4,718 3,263
Other Noncurrent Operating Assets		 1,577 1,328 1,016
Total Liabilities & Shareholders' Equity		 102,624 99,655 95,015
Total Liabilities		 63,164 61,953 59,425
Total Current Liabilities		 27,866 30,542 26,293
Short-Term Debt		 2,337 5,129 5,314
Accounts Payable		 22,465 22,374 19,040
Current Deferred & Payable Income Tax Liabilities		 1,406 1,584 896
Other Current Liabilities		 1,658 1,455 1,043
Total Noncurrent Liabilities		 35,298 31,411 33,132
Long-Term Debt		 26,506 22,365 22,965
Capital Lease Obligations		 1,113 857 725
Noncurrent Deferred & Payable Income Tax Liabilities		 3,543 2,844 2,944
Noncurrent Employee Benefit Liabilities		 1,330 1,520 1,168
Other Noncurrent Operating Liabilities		 2,806 3,825 5,330
Total Equity & Noncontrolling Interests		 39,460 37,702 35,590
Total Preferred & Common Equity		 81,657 78,309 74,095
Preferred Stock		 35,226 35,188 35,155
Total Common Equity		 4,149 2,491 414
Common Stock		 388 388 387
Retained Earnings		 3,160 1,502 -574
Other Equity Adjustments		 601 601 601
Noncontrolling Interest		 85 23 21

Annual Metrics And Ratios for AstraZeneca

This table displays calculated financial ratios and metrics derived from AstraZeneca's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 13.30% 12.45% 32.35% 11.75% 39.16% -4.52% -0.16% -3.72% -3.67% 0.00%
EBITDA Growth		 10.37% 52.44% 131.78% -57.29% 409.06% -30.18% -66.53% -5.36% -14.67% 0.00%
EBIT Growth		 6.02% 84.50% 5,449.13% -101.47% 301.37% -30.18% -66.53% -5.36% 4.59% 0.00%
NOPAT Growth		 6.14% 75.99% 673.00% -89.01% 438.86% -65.39% -48.14% -11.75% 19.07% 0.00%
Net Income Growth		 6.02% 84.50% 5,449.13% -101.47% 856.48% -70.76% -68.10% 0.60% 5.73% 0.00%
EPS Growth		 18.11% 80.57% 0.00% 0.00% 136.89% -39.41% -28.27% -14.13% 23.77% 0.00%
Operating Cash Flow Growth		 19.65% 2.69% 34.74% 63.93% 129.61% -62.60% 121.88% -13.68% -19.73% 0.00%
Free Cash Flow Firm Growth		 -4.81% 161.30% -121.64% -139.77% 761.46% -60.00% -14.57% -23.23% 0.00% 0.00%
Invested Capital Growth		 5.78% 2.55% 196.96% 250.45% -77.53% -5.23% -8.79% 7.89% 2.13% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 68.60% 66.53% 63.69% 65.88% 62.83% 79.82% 67.17% 70.94% 71.05% 72.74%
EBITDA Margin		 38.77% 39.80% 29.36% 16.76% 43.87% 11.99% 16.40% 48.91% 49.76% 56.17%
Operating Margin		 31.00% 33.09% 21.14% 5.17% 36.81% 11.99% 26.22% 48.03% 55.69% 45.44%
EBIT Margin		 28.31% 30.26% 18.44% -0.46% 34.59% 11.99% 16.40% 48.91% 49.76% 45.83%
Profit (Net Income) Margin		 28.31% 30.26% 18.44% -0.46% 34.59% 5.03% 16.43% 51.42% 49.21% 44.83%
Tax Burden Percent		 100.00% 100.00% 100.00% 65.28% 100.00% 79.26% 100.00% 105.12% 98.90% 97.82%
Interest Burden Percent		 100.00% 100.00% 100.00% 153.18% 100.00% 52.94% 100.19% 100.01% 100.01% 100.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 20.74% 0.00% -5.12% 1.10% 1.92%
Return on Invested Capital (ROIC)		 32.23% 31.64% 27.24% 10.88% 81.84% 9.05% 24.30% 46.49% 55.34% 46.97%
ROIC Less NNEP Spread (ROIC-NNEP)		 24.73% 24.49% -33.47% 22.40% -6.18% -0.03% 5.98% 48.39% 40.19% 47.80%
Return on Net Nonoperating Assets (RNNOA)		 14.69% 14.95% -2.04% -11.55% -0.37% -0.03% 5.87% 39.93% 25.62% 25.45%
Return on Equity (ROE)		 46.92% 46.59% 25.20% -0.66% 81.47% 9.02% 30.17% 86.43% 80.96% 72.42%
Cash Return on Invested Capital (CROIC)		 26.61% 29.13% -71.99% -100.32% 208.45% 14.42% 33.49% 38.90% 53.23% 0.00%
Operating Return on Assets (OROA)		 17.65% 17.28% 9.17% -0.20% 18.32% 4.79% 6.75% 19.88% 21.57% 21.05%
Return on Assets (ROA)		 17.65% 17.28% 9.17% -0.20% 18.32% 2.01% 6.77% 20.90% 21.33% 20.59%
Return on Common Equity (ROCE)		 4.04% 1.85% 1.07% -0.11% 54.73% 6.54% 17.07% 51.67% 54.67% 54.08%
Return on Equity Simple (ROE_SIMPLE)		 22.17% 21.80% 12.49% -0.22% 37.54% 11.07% 15.83% 41.62% 41.47% 33.42%
Net Operating Profit after Tax (NOPAT)		 19,821 18,674 10,611 1,373 12,489 2,318 6,697 12,914 14,634 12,290
NOPAT Margin		 31.00% 33.09% 21.14% 3.62% 36.81% 9.50% 26.22% 50.49% 55.08% 44.56%
Net Nonoperating Expense Percent (NNEP)		 7.50% 7.15% 60.72% -11.52% 88.02% 9.08% 18.32% -1.90% 15.15% -0.82%
Return On Investment Capital (ROIC_SIMPLE)		 28.55% 28.27% 16.43% - - - - - - -
Cost of Revenue to Revenue		 16.83% 15.61% 25.76% 33.99% 16.79% 20.18% 20.84% -2.81% -10.53% -4.42%
SG&A Expenses to Revenue		 31.12% 34.77% 34.48% 38.52% 33.78% 47.91% 39.46% 40.01% 35.43% 40.29%
R&D to Revenue		 21.24% 19.38% 19.45% 25.68% 17.66% 24.85% 23.23% 22.51% 22.17% 21.74%
Operating Expenses to Revenue		 52.17% 51.30% 53.10% 60.71% 46.40% 72.76% 52.94% 54.78% 54.84% 58.98%
Earnings before Interest and Taxes (EBIT)		 18,102 17,074 9,254 -173 11,736 2,924 4,188 12,511 13,219 12,639
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 24,790 22,461 14,734 6,357 14,885 2,924 4,188 12,511 13,219 15,491
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 24.48 40.40 0.00 26.14 9.45 4.20 6.15 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.59 1.78 0.00 1.86 1.74 2.26 1.59 0.00 0.00 0.00
Price to Earnings (P/E)		 5.61 5.89 0.00 0.00 5.06 26.79 10.19 0.00 0.00 0.00
Dividend Yield		 3.77% 2.23% 2.27% 2.61% 3.12% 3.22% 4.37% 4.97% 6.62% 5.58%
Earnings Yield		 17.83% 16.98% 0.00% 0.00% 19.76% 3.73% 9.81% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.52 2.62 0.00 6.55 13.89 2.69 2.24 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.49 2.77 0.00 3.39 2.29 2.74 2.30 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 6.42 6.96 0.00 20.21 5.22 22.89 14.05 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 8.80 9.16 0.00 0.00 6.63 22.89 14.05 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 8.03 8.38 0.00 93.60 6.23 28.88 8.79 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.61 10.12 0.00 11.50 11.41 22.54 7.41 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 9.73 9.10 0.00 0.00 2.44 18.12 6.38 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.76 0.75 0.81 0.81 1.42 1.24 1.52 1.17 1.10 0.88
Long-Term Debt to Equity		 0.70 0.62 0.67 0.76 1.27 1.11 1.38 1.02 0.95 0.83
Financial Leverage		 0.59 0.61 0.06 -0.52 0.06 0.88 0.98 0.83 0.64 0.53
Leverage Ratio		 2.66 2.70 2.75 3.31 4.45 4.49 4.46 4.14 3.80 3.52
Compound Leverage Factor		 2.66 2.70 2.75 5.06 4.45 2.38 4.47 4.14 3.80 3.52
Debt to Total Capital		 43.15% 42.92% 44.90% 44.67% 58.68% 55.28% 60.26% 53.93% 52.47% 46.85%
Short-Term Debt to Total Capital		 3.37% 7.77% 8.23% 2.43% 6.38% 5.58% 5.53% 6.80% 7.20% 2.85%
Long-Term Debt to Total Capital		 39.79% 35.16% 36.68% 42.24% 52.31% 49.69% 54.73% 47.12% 45.27% 44.00%
Preferred Equity to Total Capital		 50.75% 53.27% 54.42% 51.36% 23.17% 0.00% 13.96% 13.30% 13.58% 13.40%
Noncontrolling Interests to Total Capital		 0.12% 0.03% 0.03% 0.03% 0.05% 4.50% 4.97% 5.09% 5.67% 0.06%
Common Equity to Total Capital		 5.98% 3.77% 0.64% 3.95% 18.10% 40.22% 20.81% 27.68% 28.28% 39.69%
Debt to EBITDA		 1.21 1.26 1.97 4.81 1.36 6.17 4.56 1.42 1.27 0.97
Net Debt to EBITDA		 0.90 0.92 1.45 3.59 0.73 3.53 2.93 0.97 0.76 0.49
Long-Term Debt to EBITDA		 1.11 1.03 1.61 4.54 1.21 5.55 4.14 1.24 1.10 0.91
Debt to NOPAT		 1.51 1.52 2.73 22.25 1.62 7.78 2.85 1.38 1.15 1.22
Net Debt to NOPAT		 1.13 1.10 2.01 16.63 0.87 4.46 1.83 0.94 0.69 0.62
Long-Term Debt to NOPAT		 1.39 1.24 2.23 21.04 1.44 7.00 2.59 1.20 0.99 1.15
Altman Z-Score		 2.17 2.05 0.00 1.06 1.88 1.28 1.29 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 91.39% 96.04% 95.76% 82.85% 32.82% 27.47% 43.42% 40.22% 32.48% 25.32%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.93 0.82 0.86 1.16 0.96 0.86 0.96 0.80 0.87 1.08
Quick Ratio		 0.67 0.60 0.65 0.71 0.75 0.66 0.71 0.59 0.69 0.91
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 16,364 17,190 -28,042 -12,652 31,811 3,693 9,231 10,805 14,076 0.00
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 770.03% 2,222.36% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 2.58 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 2.07 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 2.87 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.62 0.57 0.50 0.44 0.53 0.40 0.41 0.41 0.43 0.46
Accounts Receivable Turnover		 5.10 4.98 4.98 4.55 5.31 4.30 4.83 5.34 4.75 4.16
Inventory Turnover		 2.01 1.74 1.84 1.93 1.56 1.38 1.54 0.00 0.00 0.00
Fixed Asset Turnover		 6.51 6.30 5.67 4.35 4.26 3.23 3.40 3.54 4.01 4.30
Accounts Payable Turnover		 0.48 0.43 0.68 0.74 0.38 0.37 0.43 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 71.64 73.24 73.33 80.21 68.75 84.84 75.63 68.37 76.90 87.64
Days Inventory Outstanding (DIO)		 181.65 209.77 198.35 189.38 233.39 264.61 236.90 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 760.37 858.19 536.16 491.66 953.56 994.94 839.69 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -507.08 -575.18 -264.48 -222.06 -651.42 -645.50 -527.16 68.37 76.90 87.64
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 63,219 59,762 58,278 19,625 5,600 24,922 26,297 28,831 26,722 26,164
Invested Capital Turnover		 1.04 0.96 1.29 3.01 2.22 0.95 0.93 0.92 1.00 1.05
Increase / (Decrease) in Invested Capital		 3,457 1,484 38,653 14,025 -19,322 -1,375 -2,534 2,109 558 0.00
Enterprise Value (EV)		 159,229 156,436 0.00 128,490 77,768 66,923 58,861 0.00 0.00 0.00
Market Capitalization		 101,570 100,629 0.00 70,515 58,872 55,128 40,605 0.00 0.00 0.00
Book Value per Share		 $2.68 $1.61 $0.27 $2.06 $4.75 $10.36 $5.21 $7.22 $7.16 $10.09
Tangible Book Value per Share		 ($34.87) ($35.90) ($37.93) ($13.18) ($4.28) ($15.29) ($21.37) ($22.81) ($23.86) ($17.16)
Total Capital		 69,416 66,053 64,594 68,391 34,405 32,635 31,717 33,021 32,031 32,127
Total Debt		 29,956 28,351 29,004 30,548 20,190 18,039 19,113 17,807 16,808 15,053
Total Long-Term Debt		 27,619 23,222 23,690 28,888 17,996 16,217 17,359 15,560 14,501 14,137
Net Debt		 22,348 20,596 21,370 22,830 10,909 10,326 12,253 12,189 10,053 7,655
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 -1,134 1,031 161 -63 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5,410 -6,437 -4,878 -1,171 -6,703 -6,986 -4,885 -5,568 -5,616 -4,801
Debt-free Net Working Capital (DFNWC)		 298 -359 1,614 5,310 1,431 -732 1,053 -986 313 2,054
Net Working Capital (NWC)		 -2,039 -5,488 -3,700 3,650 -763 -2,554 -701 -3,233 -1,994 1,138
Net Nonoperating Expense (NNE)		 1,719 1,600 1,357 1,546 753 1,091 2,501 -239 1,560 -75
Net Nonoperating Obligations (NNO)		 23,759 22,060 22,688 -18,218 -8,615 10,326 13,693 13,617 11,499 9,090
Total Depreciation and Amortization (D&A)		 6,688 5,387 5,480 6,530 3,149 0.00 0.00 0.00 0.00 2,852
Debt-free, Cash-free Net Working Capital to Revenue		 -8.46% -11.41% -9.72% -3.09% -19.75% -28.65% -19.13% -21.77% -21.14% -17.41%
Debt-free Net Working Capital to Revenue		 0.47% -0.64% 3.22% 14.00% 4.22% -3.00% 4.12% -3.85% 1.18% 7.45%
Net Working Capital to Revenue		 -3.19% -9.73% -7.37% 9.63% -2.25% -10.47% -2.75% -12.64% -7.51% 4.13%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $4.54 $3.84 $2.12 $0.00 $2.44 $1.03 $1.70 $2.37 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 1.55B 1.55B 1.55B 0.00 1.31B 1.30B 1.27B 1.27B 0.00 0.00
Adjusted Diluted Earnings per Share		 $4.50 $3.81 $2.11 $0.00 $2.44 $1.03 $1.70 $2.37 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 1.56B 1.56B 1.56B 0.00 1.31B 1.30B 1.27B 1.27B 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.55B 1.55B 1.55B 0.00 1.31B 1.31B 1.27B 1.27B 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 13,875 13,072 7,428 1,373 8,742 2,318 4,688 8,600 14,634 12,290
Normalized NOPAT Margin		 21.70% 23.16% 14.80% 3.62% 25.76% 9.50% 18.36% 33.62% 55.08% 44.56%
Pre Tax Income Margin		 28.31% 30.26% 18.44% -0.70% 34.59% 6.35% 16.43% 48.92% 49.76% 45.83%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 2.04 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 1.62 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 2.83 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 2.41 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 292.75% 83.03% 26.75% 27.24% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 292.75% 83.03% 26.75% 27.24% 0.00%

Quarterly Metrics And Ratios for AstraZeneca

No quarterly metrics and ratios for AstraZeneca are available.

Frequently Asked Questions About AstraZeneca's Financials

When does AstraZeneca's financial year end?

According to the most recent income statement we have on file, AstraZeneca's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AstraZeneca's net income changed over the last 9 years?

AstraZeneca's net income appears to be on an upward trend, with a most recent value of $18.10 billion in 2024, rising from $12.37 billion in 2015. The previous period was $17.07 billion in 2023. Check out AstraZeneca's forecast to explore projected trends and price targets.

What is AstraZeneca's operating income?
AstraZeneca's total operating income in 2024 was $19.82 billion, based on the following breakdown:
  • Total Gross Profit: $43.87 billion
  • Total Operating Expenses: $33.36 billion
How has AstraZeneca revenue changed over the last 9 years?

Over the last 9 years, AstraZeneca's total revenue changed from $27.58 billion in 2015 to $63.94 billion in 2024, a change of 131.8%.

How much debt does AstraZeneca have?

AstraZeneca's total liabilities were at $63.16 billion at the end of 2024, a 2.0% increase from 2023, and a 52.0% increase since 2015.

How much cash does AstraZeneca have?

In the past 9 years, AstraZeneca's cash and equivalents has ranged from $3.32 billion in 2017 to $7.83 billion in 2020, and is currently $5.49 billion as of their latest financial filing in 2024.

How has AstraZeneca's book value per share changed over the last 9 years?

Over the last 9 years, AstraZeneca's book value per share changed from 10.09 in 2015 to 2.68 in 2024, a change of -73.5%.


Related Companies

This page (NASDAQ:AZN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...
Weiss Ratings | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored